Skip to main content
AMRN logo

AMRN · Amarin Corp Plcuk

Track AMRN — free
$11.09 -0.17 (-1.51%)
Market Cap
$473.40M
Shares
42.04M
Volume · Nov 20 40.58K Avg daily vol (3M) 76.61K

Price & Indicators

 

Key stats

Close
$11.26
Thu 19 Nov
Open
$11.26
Thu 19 Nov
Average volume, 30 days
79K
shares a session
Short interest
538K
1.3% of shares · 7.6 days to cover
Day range
$11.17$11.37
Open $11.26 Close $11.26
52-week closing range
$11.26$16.98
Close $11.26 33.7% under the high
Short volume, last session
52%
Last earnings
Oct 28, 2026
Latest filing
10-Q · Oct 28
Price history
Jan 2020 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Current report 8-K Events of Nov 16
Director Patrice Bonfiglio resigns effective immediately, citing no disagreement

Patrice Bonfiglio notified Amarin Corporation plc on November 16, 2026 of her decision to resign as a director, effective immediately. The resignation is not the result of any disagreement with the Company on its operations, policies or practices.

Director or officer change, or executive pay
2 source passages
On November 16, 2026, Ms. Patrice Bonfiglio notified Amarin Corporation plc (the “Company”) of her decision to resign as a director of the Company, effective immediately. Ms. Bonfiglio’s decision to resign is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Open the document at this passage
Oct 28
Earnings call
Third-Quarter Revenue Falls to $39.6 Million; Net Income $245,000

Third-quarter 2026 net revenue was $39.6 million, down from $49.7 million a year earlier, and net income was $245,000. A colorectal cancer trial of the drug missed its primary progression-free survival endpoint but showed a 32% lower hazard of death in overall survival.

4 source passages
Total net revenue in the third quarter of 2026 was $39.6 million, compared to $49.7 million in the third quarter of 2025. net income for the quarter was $245,000, or less than $0.01 per share Importantly, while the primary endpoint of progression-free survival was not met, the study demonstrated an improvement in the key secondary endpoint of overall survival. A statistically significant 32% lower hazard of death, which is a meaningful finding in a patient population where up to 60% of patients may experience disease recurrence within two years following surgery. Open the document at this passage
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls 20% to $39.6 million on lower US sales

Amarin reported total revenue, net, of $39.6 million for the three months ended September 30, 2026, down $10.1 million, or 20%, from $49.7 million a year earlier. The decrease was due primarily to a $12.3 million decline in U.S. net product revenue. Gross margin on product sales fell to 37% from 43%, mainly due to a change in customer mix.

Revenue $39.55M ▼ 20.4% Net income $245K Diluted EPS $0.00
Read from the MD&A section
4 source passages
We recorded total revenue, net, of $39.6 million and $49.7 million during the three months ended September 30, 2026 and 2025, respectively, a decrease of $10.1 million, or 20%. As further discussed below, the aforementioned decrease was due primarily to a $12.3 million decrease in U.S. net product revenue Our overall gross margin on product sales for the three months ended September 30, 2026 and 2025 was 37% and 43%, respectively. The decrease in gross margin was primarily as a result of a change in customer mix. Open the document at this passage
Oct 28
Current report 8-K
Third-quarter net income turns positive at $0.2 million

Amarin reported third-quarter 2026 net income of $0.2 million, against a net loss of $(7.7) million a year earlier. Total net revenue fell 20% to $39.6 million. Cash and short-term investments reached $323.4 million, and the company remains debt-free.

Financial results
5 source passages
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income Net Loss | $0.2 | $(7.7) | 103% Total Net Revenue | $39.6 | $49.7 | (20)% | $126.9 | $164.4 | (23)% Cash, Cash Equivalents & Short-Term Investments | $302.6 | $307.8 | $314.6 | $323.4 | ~$330 Our cash balance now exceeds $323 million and our balance sheet remains debt-free. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$176.11M
Trailing 12 months
Net income (TTM)
−$19.14M
Trailing 12 months
Revenue growth YoY
-20.4%
Year over year
Operating margin
-18.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.0%
Year over year · more shares
Price change (1Y)
-33.7%
Trailing year
Short interest
1.3%
Latest settlement · 7.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 28, 2026
Q3 FY26

TL;DR. Amarin returned to quarterly profitability, cut Q3 operating expenses 44%, generated positive operating cash flow, ended with $323.4 million of cash and investments and no debt, while global partner-network in-market demand rose 55% and U.S. IPE share held at 47%; it expects positive Q4 operating cash flow and about $330 million of cash. Revenue declined 20% amid U.S. generic-driven pricing pressure, partner purchasing may not match international demand growth, and EMT2 missed its primary endpoint despite a statistically significant overall-survival benefit.

Bullish
  • + Returned to quarterly profitability, reporting $245,000 of net income versus a $7.7 million loss new
  • + Cut Q3 operating expenses 44% and expects further reductions in Q4 new
  • + Improved year-to-date operating cash flow to $22 million from a $9 million outflow new
  • + Maintained U.S. IPE market leadership with 47% share and expects broadly stable volumes new
  • + EMT2 showed a statistically significant 32% lower hazard of death new
Bearish
  • − Partner purchasing may not grow in line with international in-market demand new
  • − EMT2 failed to meet its primary progression-free-survival endpoint new
  • − 2027 payer exclusivities remain unconfirmed amid normal product-exclusivity changes new
  • − Q3 remained GAAP operating-loss-making despite returning to net profitability new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −9%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −3%
trailing
6-month return −22%
trailing
YTD return −19%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $14 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.28% of shares out · ▲ +1.0% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
82 holders — mid 3-yr range
Squeeze score 49
elevated · 0–100
Fundamentals
Excellent
Revenue growth +39%
Y/Y
Gross margin 67%
expanding
EPS growth +55%
Y/Y
Free cash flow $6.5M
Buyback $50.0M
authorized
Quant / Vol
risk profile
Moderate
Volatility 41%
annualized · 1-yr
Max drawdown −34%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 28, 2026
Cash, Cash Equivalents & Short-Term Investments · FY 2026 Expectations $330M
Previous outlook earlier release · from the 8-K filed Jul 29, 2026

Still-open targets the latest release did not restate under the same label.

Cash growth · as of December 31, 2026 compared to December 31, 2025 10%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $12 › 200d $14 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.28% of shares out · ▲ +1.0% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
82 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11 Now $11 · 0% Range high $17
vs 200-day avg -20% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
commercially available 22 As of June 30, 2026 —
in-market demand for VASCEPA/VAZKEPA 59% Q2 2026 —
in-market demand in Europe 69% Q2 2026 —
in-market volume in China 90% year-to-date —
Net income (loss) for EPS1 - non-GAAP non-GAAP -1M Six months ended June 30, 2026 —
share of the U.S. IPE market 48% Q2 2026 —
VASCEPA branded prescriptions 14% Q2 2026 —
VAZKEPA is commercialized in 11 As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AMRN
Amarin Corp Plcuk
this stock
$473.40M -19.3% +39.2% — 1.3%
LLY
ELI LILLY & Co
$1.27T +25.7% +44.7% 43.9 0.8%
JNJ
Johnson & Johnson
$643.09B +29.1% +6.0% 40.6 0.7%
ABBV
AbbVie Inc.
$501.19B +24.1% +8.6% 48.8 0.9%
MRK
Merck & Co., Inc.
$327.41B +26.2% +1.3% 136.9 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
82
% held
10.6%
Net QoQ
-150.1K sh
Top holder
Sarissa Capital Managemen…
Held Float
View
Held by Funds
Fund positions
13
View
Short & Settlement
Short Interest Rising
Shares short
537.9K
Days to cover
7.6d
Change
+5.2K sh
View
Short Volume
Short vol %
52%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$12
As of
Oct 6, 2026
View
Off-Exchange
Off-exchange %
44.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$213.6M
Net income (FY)
$-38.8M
EPS diluted
$-0.09
View
Buybacks
Authorized
$50.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 18, 2026
This year
15

Patrice Bonfiglio notified Amarin Corporation plc on November 16, 2026 of her decision to resign as a director, effective immediately. The resignation is not the result of any disagreement with the Company on its operations, policies or practices.

View
Proposed Sales
Value
$28.6K
Shares
34.1K
Filed
Dec 12, 2023
View
Earnings & Events
Webcasts
Last webcast
Oct 28, 2026
View
Investor Relations
Latest news
Amarin Highlights New Data on Lip…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
AMRN -3.5% -2.9% -21.6% -7.0% -19.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +1.9% +3.4% -16.0% -1.8% -24.3%

Capital returns

Buyback program · as of Jan 10, 2024
Authorized
$50.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 897448 CUSIP 023111404 13F (30d) 87 filings 77 filers Visit website Investor relations